INTRODUCTION {#s1}
============

Interleukin-18 (IL-18) is a member of the IL-1 cytokine family \[[@ref1]\]. It is secreted by various immune and nonimmune cells including T and B lymphocytes, activated monocytes, macrophages, Kupffer cells, natural killer cells, and Langerhans cells \[[@ref2],[@ref3],[@ref4]\]. Evidence has shown that IL-18 has both anticancer and procancer effects \[[@ref5]\]. IL-18 can stimulate natural killer cells and T cells promoting primarily Th1 responses, resulting in the elimination of tumor cells \[[@ref6],[@ref7],[@ref8],[@ref9]\]. On the other hand, it has been reported that IL-18 is able to induce angiogenesis, migration, proliferation, and immune escape of tumor cells \[[@ref10]\]. In models of hepatic melanoma metastasis the IL-18 blockade reduces the adherence of malignant cells by preventing IL-18 upregulation of vascular endothelial adhesion-1 molecule expression \[[@ref11]\]. Higher expression levels of IL-18 are detected in different cancer types, such as gastric and breast cancer \[[@ref12],[@ref13]\]. These results suggest that there is an association between the IL-18 gene and cancer risk, but this still remains controversial.

The IL-18 gene is located on chromosome 11q22.2-q22.23. A number of single nucleotide polymorphisms (SNPs) have been identified and investigated \[[@ref14]\]. The IL-18 gene promoter -137G/C (rs187238) polymorphism is one of the most common SNPs, relative to the transcriptional start site, which may alter the expression of IL-18. This polymorphism can change the binding site of histone 4 transcription factor-1 nuclear factor and can have an impact on IL-18 gene activity \[[@ref15]\].

Chronic myelogenous leukemia (CML) is a clonal bone marrow stem cell disorder characterized by the unregulated growth of mature granulocytes in the bone marrow and their accumulation in the blood \[[@ref16]\]. The formation of the BCR-ABL fusion protein, which activates tyrosine kinase, plays a central role in the pathogenesis of CML \[[@ref17]\]. Chronic lymphocytic leukemia (CLL) is the most common type of leukemia. CLL affects B cell lymphocytes that originate in the bone marrow, develop in the lymph nodes, and normally fight infection by producing antibodies \[[@ref18]\].

It has been reported that malignant proliferation of leukemic cells is supported by a cytokine network surrounding these cells, produced partially by the cells themselves \[[@ref19]\]. Elevated levels of IL-18 were observed in some leukemia patients, especially those with acute lymphoblastic leukemia and CML \[[@ref20]\]. On the other hand, IL-18 receptor expression was reported mostly from CD19+ B cells and some CD8+ T cells \[[@ref21]\].

The aim of this study is to evaluate the frequency of IL-18 gene promoter polymorphisms in Turkish CLL and CML patient groups and compare them with a control group in order to verify a correlation between the allelic variations and the risk of CML and CLL.

MATERIALS AND METHODS {#s2}
=====================

Subjects {#s2a}
--------

Twenty unrelated CLL patients and 30 unrelated CML patients diagnosed clinically at the Gülhane Military Medical Academy Department of Hematology and a control group of 30 unrelated healthy volunteers were randomly selected from different geographic regions of Turkey. The study protocol was approved by the local ethics committee of Gülhane Military Medical Academy and was conducted in accordance with the guidelines of the Declaration of Helsinki.

Genotyping {#s2b}
----------

The SNP in the promoter region of the IL-18 gene (SNP \*g/c\...\...rs187238; \*g/t\..... rs61667799; \*c/g\...\....rs5744227; \*a/g\....rs5744228) was sequenced was determined by sequencing method. Genomic DNA was isolated from the peripheral blood by standard phenol-chloroform procedure. The genotyping of polymorphisms was performed by polymerase chain reaction and DNA sequencing analysis. A 446-bp fragment was amplified using specific primers (forward: 5'-CCAATAGGACTGATTATTCCGCA-3' and reverse: 5'-AGGAGGGCAAAATGCACTGG-3'). Amplification was carried out on a Bio-RAD PCR system in 50 µL of reaction mixture containing 10 mM dNTPs, 25 mM magnesium chloride, 5 pmol each of forward and reverse primers, 2.5 U of Taq DNA polymerase, 10X PCR buffer, and 50 ng of genomic DNA. The PCR cycling conditions consisted of an initial denaturation step at 95 °C for 5 min, followed by 30 cycles of 94 °C for 1 min, 60 °C for 1 min, and 72 °C for 1 min, with a final extension step at 72 °C for 5 min. PCR products of 446 bp were then separated by 2% agarose gel electrophoresis at 120 V, stained by ethidium bromide (0.5 µg/mL), and visualized under a UV transilluminator. Single-pass sequencing was performed on each template using the forward primer. Cycle sequencing was carried out using the BigDye Terminator v.3.1 Cycle Sequencing Kit (Applied Biosystems, USA) according to the manufacturer's instructions. The fluorescence-labeled fragments were purified by sodium acetate-ethanol precipitation method. Samples were then resuspended in distilled water and subjected to electrophoresis in an ABI PRISM 3100 Genetic Analyzer (Applied Biosystems).

Statistical Analysis {#s2c}
--------------------

SPSS 16.0 (SPSS Inc., USA) was used for the statistical analysis. Allele and genotype frequencies of alleles and genotypes were obtained by direct count. Statistical significance was defined as p\<0.05.

RESULTS {#s3}
=======

Genotypes of the CML and CLL patients and the controls were determined by using DNA sequencing methodology for promoter polymorphisms. [Figure 1](#f1){ref-type="fig"} shows the chromatograms, which contain DNA fragments representing homozygous wild-type, heterozygous, and homozygous mutant genotypes (rs187238 G/C). The genotype and allele distributions of the controls versus CML and CLL patients are given in [Tables 1](#t1){ref-type="table"} and [2](#t2){ref-type="table"}, respectively.

Among the control group subjects, 77% were found to be homozygous for the GG genotype and 23% were heterozygous. There were no subjects with the CC genotype. The G allele frequency was 88% and C allele frequency was 12%. Among the CLL patients, 70% were found to be homozygous for the GG genotype, 10% were heterozygous (GC), and 20% were homozygous for the CC genotype. The G allele frequency was found as 75% whereas C allele frequency was 25%. Among the CML patients, 50% were found to be homozygous for the GG genotype, 37% were heterozygous (GC), and 13% were homozygous for the CC genotype. The G allele frequency was found as 68% whereas C allele frequency was 32%.

A higher prevalence of the C allele was found in CML patients with respect to the controls (p\<0.05; [Table 1](#t1){ref-type="table"}). The GC heterozygous and CC homozygous genotypes were associated with the risk of CML when compared with the controls (OR: 1.9023; 95% CI: 0.6171-5.8636 for GC genotype and OR: 10.3585; 95% CI: 0.5326-201.4622 for CC genotype). These results indicate that individuals that are either heterozygous (GC) or homozygous for the CC genotype are associated with the development of CML in this Turkish population. However, prevalence of the C allele was not significantly high in CLL patients with respect to controls (p\>0.05). There was only a significant difference between the homozygous CC genotype of CLL patients and the control group (p\<0.05; [Table 2](#t2){ref-type="table"}). The CC homozygous genotype is associated with the risk of CLL when compared with controls (OR: 16.6364; 95% CI: 0.8428-328.3734). This indicates that homozygosity for the CC genotype was associated with the development of CLL in the studied patient group. There were no significant associations between the IL-18 rs61667799(G/T), rs5744227(C/G), or rs5744228(A/G) polymorphisms and CLL or CML.

DISCUSSION {#s4}
==========

The -137G/C (rs187238) SNP in the promoter region of the IL-18 gene has a confirmed impact on gene activity and expression in tissues \[[@ref15],[@ref22]\]. Some previous studies have suggested that IL-18 might act as a protumor factor in the progress of several tumors. The IL-18 protein has been shown to be overexpressed expressed in common skin tumors \[[@ref1],[@ref23]\]. On the other hand, higher IL-18 levels both in the tumor region and in the serum were detected in metastatic gastric and breast cancer \[[@ref12],[@ref13],[@ref24]\]. Furthermore, linkage between -137G/C and -607C/A polymorphisms of the IL-18 gene and progression of ovarian cancer and nasopharyngeal carcinoma was reported \[[@ref25],[@ref26]\].

Based on 21 different studies, carriers of the variant C allele for -137G/C polymorphism were only reported to have a significant increased cancer risk compared with carriers of the G allele in nasopharyngeal carcinoma \[[@ref27]\]. In the dominant CC genotype, some single studies suggested that the -137G/C polymorphism contributed to the susceptibility to certain cancer types, such as cervical \[[@ref28]\], prostate \[[@ref29]\], bladder \[[@ref30]\], esophageal \[[@ref31]\], and colorectal \[[@ref32]\]. There are also several studies that concluded that there was no significant association between cancer and the -137G/C polymorphism \[[@ref5],[@ref33],[@ref34]\]. Moreover, in one study, Monroy et al. found a significantly reduced cancer risk with the GC/CC genotype in Hodgkin disease \[[@ref35]\].

These discrepant conclusions might be explained by ethnic differences since the studies that reported increased cancer risk were almost all carried out in Asians. On the contrary, a trend of reduced cancer risk was found in Caucasians \[[@ref27]\].

To our knowledge, there are not many reports describing a comprehensive relation between -137G/C polymorphism and susceptibility to CML and CLL. In the present study, potential influence of the -137G/C polymorphism on both CLL and CML susceptibility was considered in a Turkish population. Our results showed a significantly increased risk in heterozygous (GC) and homozygous (CC) genotypes for CML. On the other hand, only the homozygous (CC) genotype is associated with the risk of CLL when compared with the controls. The results of this study may be important since there are not many reports showing the association of the -137G/C polymorphism with the risk of CML and CLL. However, there are several studies that showed dysregulated expression of IL-18 and/or IL-18 receptor in chronic B-cell lymphoproliferative disorders \[[@ref36],[@ref37]\]. The dysregulated expression of IL-18 may be due to IL-18 gene promoter polymorphisms such as -137G/C. In addition, for this study, several limitations should be considered. First, the CML and CLL patient numbers were small. Second, haplotype analysis linking other IL-18 polymorphisms to IL-18 expression level may be necessary.

In conclusion, we demonstrate that IL-18 gene promoter -137G/C polymorphism is associated with CLL and CML in a Turkish population. However, due to the limited number of studied patients, these are only preliminary results that show the association between the -137G/C polymorphism and CLL and CML. Further large-scale studies combined with haplotype and expression analysis are required to validate the current findings.
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